Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease

Neuropsychopharmacology

Volumn 37, Issue 8, 2012, Pages 1934-1944

  Francis, Beverly M ^a,b   Yang, Jimao ^a   Hajderi, Enid ^a   Brown, Mary E ^b   Michalski, Bernadeta ^c   McLaurin, Joanne ^b   Fahnestock, Margaret ^c   Mount, Howard T J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

amyloid; BDNF; dexefaroxan; memory; noradrenaline; rivastigmine

Indexed keywords

3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; DESIPRAMINE; DOPAMINE; EFAROXAN; HOMOVANILLIC ACID; MESSENGER RNA; NORADRENALIN; PRESYNAPTIC RECEPTOR; RIVASTIGMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN STEM; CEREBELLUM; CHOLINERGIC NERVE; CONTROLLED STUDY; CORPUS STRIATUM; EXPERIMENTAL MODEL; FRONTAL CORTEX; GENE EXPRESSION; GENOTYPE; GROUPS BY AGE; HIPPOCAMPUS; MEMORY DISORDER; MESENCEPHALON; MOUSE; NERVE ENDING; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENERGIC NERVE; PARIETAL CORTEX; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TEMPORAL CORTEX; TRANSGENIC MOUSE;

ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BENZOPYRANS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINES; CHOLINESTERASE INHIBITORS; DESIPRAMINE; DISEASE MODELS, ANIMAL; IMIDAZOLES; IMMOBILITY RESPONSE, TONIC; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENYLCARBAMATES; RECOGNITION (PSYCHOLOGY);

EID: 84862306099     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.40     Document Type: Article

References (76)

1. Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979). Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135: 216-223. (Pubitemid 9244805)
2. Ambree O, Richter H, Sachser N, Lewejohann L, Dere E, de Souza Silva MA et al (2009). Levodopa ameliorates learning and memory deficits in a murine model of Alzheimer's disease. Neurobiol Aging 30: 1191-1204.
3. Barfield ET, Barry SM, Hodgin HB, Thompson BM, Allen SS, Grisel JE (2010). β-endorphin mediates behavioral despair and the effect of ethanol on the tail suspension test in mice. Alcohol Clin Exp Res 34: 1066-1072.
4. Bellucci A, Luccarini I, Scali C, Prosperi C, Garzia M, Giovannini MG et al (2006). Cholinergic dysfunction, neuronal damage and axonal loss in TgCRND8 mice. Neurobiol Dis 23: 260-272. (Pubitemid 44080837)
5. Berridge CW, Waterhouse BD (2003). The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev 42: 33-84. (Pubitemid 36369264)
6. Bondareff W, Mountjoy CQ, Roth M (1982). Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 32: 164-168. (Pubitemid 12223999)
7. Bondareff W, Mountjoy CQ, Roth M, Rossor MN, Iversen LL, Reynolds GP et al (1987). Neuronal degeneration in locus coeruleus and cortical correlates of Alzheimer's disease. Alzheimer Dis Assoc Discord 1: 256-262.
8. Braak H, Braak E (1991). Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259.
9. Braak H, Del Tredici K (2004). Alzheimer's disease: intraneuronal alterations precede insoluble amyloid-β formation. Neurobiol Aging 25: 713-718. (Pubitemid 38698242)
10. Chen L, Cagniard B, Mathews T, Jones S, Koh HC, Ding Y et al (2005). Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280: 21418-21426. (Pubitemid 40805706)
11. Chishti MA, Yang D, Janus C, Phinney A, Horne P, Pearson J et al (2001). Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276: 21562-21570. (Pubitemid 37413154)
12. 2-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J Pharmacol Exp Ther 301: 187-196.
13. Counts S, Mufson E (2010). Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem 113: 649-660.
14. Coyle JT, Duman RS (2003). Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38: 57-160.
15. Coyle JT, Price DL, DeLong MR (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219: 1184-1190. (Pubitemid 13160659)
16. Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29: 571-625. (Pubitemid 40755457)
17. Davies P, Maloney AJ (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403. (Pubitemid 8004505)
18. 2-adrenoceptor antagonist, dexefaroxan, against degeneration of the basalocortical cholinergic system induced by cortical devascularization in the adult rat. Neuroscience 115: 41-53.
19. DeToledo-Morrell L, Sullivan MP, Morrell F, Wilson RS, Bennett DA, Spencer S (1997). Alzheimer's disease: in vivo detection of differential vulnerability of brain regions. Neurobiol Aging 18: 463-468. (Pubitemid 27497141)
20. Dringenberg HC (2000). Alzheimer's disease: more than a 'cholinergic disorder'-evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav Brain Res 115: 235-249.
21. Engberg G, Svensson TH (1980). Pharmacological analysis of a cholinergic receptor mediated regulation of brain norepinephrine neurons. J Neural Transm 49: 137-150. (Pubitemid 11243234)
22. Finkel SI (2004). Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther 26: 980-990.
23. Foote SL, Bloom FE, Aston-Jones G (1983). Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol Rev 63: 844-914. (Pubitemid 13048718)
24. Forno LS (1966). Pathology of Parkinsonism. J Neurosurg 24: 266-271.
25. Francis BM, Kim J, Barakat ME, Fraenkl S, Yucel YH, Peng S et al (2012). Object recognition memory and BDNF expression are reduced in young TgCRND8 mice. Neurobiol Aging 33: 555-563.
26. Francis PT, Palmer AM, Snape M, Wilcock GK (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Pyschiatry 66: 137-147. (Pubitemid 29103513)
27. Galeotti N, Ghelardini C (2011). Regionally selective activation and differential regulation of ERK, JNK and p38 MAP kinase signaling pathway by protein kinase C in mood modulation. Int J Neuropsychopharmacol; e-pub ahead of print 20 June 2011.
28. German DC, Manaye KF, White III CL, Woodward DJ, McIntire DD, Smith WK et al (1992). Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32: 667-676.
29. Gonzalo-Ruiz A, Gonzalez I, Sanz-Anquela JM (2003). Effects of β-amyloid protein on serotonergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chem Neuroanat 26: 153-169. (Pubitemid 38112732)
30. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007). Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 28: 327-335. (Pubitemid 46178530)
31. Hardy J, Adolfsson R, Alafuzoff I, Bucht G, Marcusson J, Nyberg P et al (1985). Transmitter deficits in Alzheimer's disease. Neurochem Int 7: 545-563. (Pubitemid 15010626)
32. Harik SI, McCracken KA (1986). Age-related increase in presynaptic noradrenergic markers of the rat cerebral cortex. Brain Res 381: 125-130. (Pubitemid 16049667)
33. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D et al (2010). Locus coeruleus controls AD pathology by modulating microglial functions through norepinephrine. PNAS 107: 6058-6063.
34. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T (2006). Locus coeruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 26: 1343-1354. (Pubitemid 43237005)
35. Herrmann N, Lanctot KL, Khan LR (2004). The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 16: 261-276. (Pubitemid 39244552)
36. Holm PC, Rodriguez FJ, Kresse A, Canals JM, Silos-Santiago I, Arenas E (2003). Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development 130: 3535-3545. (Pubitemid 37010016)
37. Ishida Y, Shirokawa T, Komatsu Y, Isobe K (2001). Changes in cortical noradrenergic axon terminals of locus coeruleus neurons in aged F344 rats. Neurosci Lett 307: 197-199. (Pubitemid 32595662)
38. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD et al (2000). Aβ peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982. (Pubitemid 32101644)
39. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A et al (2010). Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 57: 375-382.
40. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Thiele A, Heneka MT (2011). Distinct adrenergic system changes and neuroinflammation in response to induced locus coeruleus degeneration in APP/PS1 transgenic mice. Neuroscience 176: 396-407.
41. Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT et al (2007). Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 28: 1206-1214. (Pubitemid 46810064)
42. Kalinin S, Polak PE, Lin SX, Sakharkar AJ, Pandey SC, Feistein DL (2011). The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging; e-pub ahead of print 24 June 2011.
43. Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C (2008). Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 258: 124-128. (Pubitemid 351441932)
44. Ma K, Mount HTJ, McLaurin J (2011). Region-specific distribution of β-amyloid peptide and cytokine expression in TgCRND8 mice. Neurosci Lett 492: 5-10.
45. Manaye KF, McIntire DD, Mann DM, German DC (1995). Locus coeruleus cell loss in the aging human brain: a non-random process. J Comp Neurol 358: 79-87.
46. Mann DMA, Yates PO, Hawkes J (1982). The noradrenergic system in Alzheimer's and multi-infarct dementias. J Neurol Neurosurg Psychiatry 45: 113-119. (Pubitemid 12176925)
47. Marcyniuk B, Mann DMA, Yates PO (1986). The topography of cell loss from locus coeruleus in Alzheimer's disease. J Neurol Sci 76: 335-345. (Pubitemid 17176089)
48. Marien MR, Colpaert FC, Rosenquist AC (2004). Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Rev 45: 38-78. (Pubitemid 38520015)
49. Matsunaga W, Shirokawa T, Isobe K (2004). BDNF is necessary for maintenance of noradrenergic innervations in the aged rat brain. Neurobiol Aging 25: 341-348. (Pubitemid 38220970)
50. Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT (2002). Noradrenergic changes, aggressive behaviour and cognition in patients with dementia. Biol Psychiatry 51: 407-416. (Pubitemid 34251178)
51. Mejías-Aponte CA, Drouin C, Aston-Jones G (2009). Adrenergic and noradrenergic innervation of the midbrain ventral tegmental area and retrorubral field: prominent inputs from medullary homeostatic centres. Neuroscience 29: 3613-3626.
52. Meredith GE, Kang UJ (2006). Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 21: 1595-1606. (Pubitemid 44742185)
53. Moroji T, Takahashi K, Ikeda C (1978). Levels of biogenic amines and their metabolites in rat whole brain after rapid tissue fixation with microwave irradiation. No To Skinkei 30: 1303-1308.
54. Mount HTJ, Martel J-C, Fluit P,Wu Y, Gallo-Hendrikx E, Cosi C et al (2004). Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia. J Neurochem 88: 1449-1454. (Pubitemid 38366921)
55. Ohno M, Yoshimatsu A, Kobayashi M, Watanabe S (1997). Noradrenergic DSP-4 lesions aggravate impairment of working memory produced by hippocampal muscarinic blockade in rats. Pharmacol Biochem Behav 57: 257-261. (Pubitemid 27261419)
56. Palmer AM, Francis PT, Bowen DM, Benton JS, Neary D, Mann DM et al (1987b). Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res 414: 365-375. (Pubitemid 17091962)
57. Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM (1987a). Monoaminergic innervations of the frontal and temporal lobes in Alzheimer's disease. Brain Res 401: 231-238. (Pubitemid 17221814)
58. Peng S, Garzon DJ, Marchese M, Klein W, Ginsberg SD, Francis BM et al (2009). Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J Neurosci 29: 9321-9329.
59. Rizk P, Salazar J, Raisman-Vozari R, Marien M, Ruberg M, Colpaert F et al (2006). The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology 31: 1146-1157. (Pubitemid 43971832)
60. Schallert T, Upchurch M, Lobaugh N, Farrar SB, Spirduso WW, Gilliam P et al (1982). Tactile extinction: distinguishing between sensorimotor and motor asymmetries in rats with unilateral nigrostriatal damage. Pharmacol Biochem Behav 16: 455-462. (Pubitemid 12147019)
61. Srivareerat M, Tran TT, Salim S, Aleisa AM, Alkadhi KA (2011). Chronic nicotine restores normal Aβ levels and prevents short-term memory and E-LTP impairment in Aβ rat model of Alzheimer's disease. Neurobiol Aging 32: 834-844.
62. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85: 367-370. (Pubitemid 15123115)
63. Stoub TR, Rogalski EJ, Leurgans S, Bennett DA, DeToledo-Morrell L (2010). Rate of entorhinal and hippocampal atrophy in incipient and mild AD: relation to memory function. Neurobiol Aging 31: 1089-1098.
64. Strong R, Huang JS, Huang SS, Chung HD, Hale C, Burke WJ (1991). Degeneration of the cholinergic innervation of the locus coeruleus in Alzheimer's disease. Brain Res 542: 23-28.
65. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (2006). Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with lewy bodies. J Neurosci 26: 467-478. (Pubitemid 43237111)
66. Tanghe A, Termont A, Merchiers P, Schilling S, Demuth H, Scrocchi L et al (2010). Pathological Hallmarks, clinical parallels, and value for drug testing in Alzheimer's disease of the APP[V717I] London transgenic mouse model. Int J Alzheimer Dis; e-pub ahead of print 2 September 2010.
67. 2-Adrenoceptor modulation of cortical acetylcholine release in vivo. Neuroscience 89: 1041-1050.
68. Thal DR, Rub U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K et al (2000). Sequence of abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59: 733-748. (Pubitemid 30626743)
69. Thal DR, Rub U, Orantes M, Braak H (2002). Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800. (Pubitemid 34663580)
70. Traver S, Marien M, Martin E, Hirsch EC, Michel PP (2006). The phenotypic differentiation of locus coeruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol 70: 30-40.
71. Traver S, Salthun-Lassalle B, Marien M, Hirsch EC, Colpaert F, Michel PP (2005). The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol Pharmacol 67: 1882-1891. (Pubitemid 41007770)
72. Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology 180: 177-190. (Pubitemid 40897084)
73. 2-adrenoceptor antagonists counteract deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb. Exp Neurol 194: 444-456.
74. Wood PL, Altar CA (1988). Dopamine release in vivo from nigrostriatal, mesolimbic and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol Rev 40: 163-187. (Pubitemid 19019651)
75. Wood PL, Kim HS, Altar CA (1987). In Vivo assessment of dopamine and noradrenaline release in rat neocortex: gas chromatography-mass spectrometry measurement of 3-Methoxytyramine and normetanephrine. J Neurochem 48: 574-579. (Pubitemid 17005170)
76. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurology 60: 337-341. (Pubitemid 36314358)